Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 8.01, 9.01 · 8-K

BioStem Technologies, Inc.

Other Events

Item 8.01 - Other Events On August 6, 2026, BioStem Technologies, Inc. (the “Company”), announced that its shares of common stock, par value $0.001, have been approved by The Nasdaq Stock Market LLC for listing on The Nasdaq Capital Market (“Nasdaq”).…

Filed Aug 7, 2026Accepted Aug 7, 2026, 4:15 PM EDTCIK 1658678Accession 0001193125-26-340271
Share

Company context

BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

Current securities

Historical securities (5)

Recent company filings

  1. 4 filingNov 19, 2026
  2. 424B3 filingNov 19, 2026
  3. 424B3 filingNov 19, 2026
  4. 424B3 filingNov 19, 2026
  5. 10-Q filingNov 12, 2026

Registered securities in this filing

BioStem Technologies, Inc. · 8-K · Filed 2026-08-07

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.001 par value

Symbol
BSEM
Exchange
NASDAQ
Classification
COMMON
Filing context

Context: C_9e49c60e-fb05-4322-9190-58ff53c53cc5

Dimensions: Not supplied

Accession 000119312526340271 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01 - Other Events On August 6, 2026, BioStem Technologies, Inc. (the “Company”), announced that its shares of common stock, par value $0.001, have been approved by The Nasdaq Stock Market LLC for listing on The Nasdaq Capital Market (“Nasdaq”). Trading in the Company’s common stock transitioned from the OTCID Basic Market to Nasdaq effective as of the opening of trading on August 7, 2026, and now trades on Nasdaq under its current ticker symbol “BSEM.” Shareholders of the Company do not need to take any action in connection with the listing of the Company’s common stock for trading on Nasdaq. For additional information, reference is made to the Company’s press release dated August 6, 2026, which is filed as Exhibit 99.1 to this report and incorporated by reference herein.
Filed exhibits (1)
EX-99.1 (by filename) bsem-ex99_1.htm

EX-99.1 2 bsem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BioStem Technologies Announces Nasdaq Uplisting Trading to Commence on August 7, 2026 POMPANO BEACH, Fla., August 6, 2026 - BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has completed its review of the Company’s listing application and approved the Company’s common stock for listing on The Nasdaq Capital Market. The Company’s common stock is expected to begin trading on Nasdaq on August 7, 2026 under the ticker symbol “BSEM.” "Our uplisting to Nasdaq is an important milestone for BioStem, reflecting the significant progress we have made in strengthening our foundation, streamlining our operations, and executing on our core business strategy," said Jason Matuszewski, Chairman and CEO of BioStem Technologies. "We believe this uplisting will expand our access to capital, improve market visibility and liquidity for our shareholders, and reinforce our ability to attract exceptional talent as we contin…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.